Ghent University Academic Bibliography

Journal Article
A1
open access

A trial-based cost-utility analysis of metastasis-directed therapy for oligorecurrent prostate cancer

Elise De Bleser (UGent) , Ruben Willems (UGent) , Karel Decaestecker (UGent) , Lieven Annemans (UGent) , Aurélie De Bruycker, Valerie Fonteyne (UGent) , Nicolaas Lumen (UGent) , Filip Ameye, Ignace Billiet, Steven Joniau, et al.

(2020) CANCERS. 12(1).

Add to list

Journal Article
A1
open access

A deep learning approach validates genetic risk factors for late toxicity after prostate cancer radiotherapy in a REQUITE Multi-National Cohort

Michela Carlotta Massi, Francesca Gasperoni, Francesca Ieva, Anna Maria Paganoni, Paolo Zunino, Andrea Manzoni, Nicola Rares Franco, Liv Veldeman (UGent) , Piet Ost (UGent) , Valerie Fonteyne (UGent) , et al.

(2020) FRONTIERS IN ONCOLOGY. 10.

Add to list

Patient- versus physician-reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within a randomized controlled trial

Elke Rammant (UGent) , Piet Ost (UGent) , Martijn Swimberghe (UGent) , Barbara Vanderstraeten (UGent) , Nicolaas Lumen (UGent) , Karel Decaestecker (UGent) , Renée Bultijnck (UGent) , Gert De Meerleer (UGent) , Camille Sarrazyn (UGent) , Roos Colman (UGent) , et al.

(2019) STRAHLENTHERAPIE UND ONKOLOGIE. 195(5). p.393-401

Add to list

What is oligometastatic prostate cancer?

Michael Fraser, Bridget Koontz, Urban Emmenegger, Gert De Meerleer, Vincent Khoo, Felix Feng, Niall M. Corcoran, Christopher M. Hovens, Phuoc T. Tran, Piet Ost (UGent) , et al.

(2019) EUROPEAN UROLOGY FOCUS. 5(2). p.159-161

Add to list

Metastasectomy for visceral and skeletal oligorecurrent prostate cancer

Antonino Battaglia, Gaetan Devos, Karel Decaestecker (UGent) , Manuel Witters, Lisa Moris, Thomas Van den Broeck, Charlien Berghen, Wouter Everaerts, Maarten Albersen, Arman Tsaturyan, et al.

(2019) WORLD JOURNAL OF UROLOGY. 37(8). p.1543-1549

Add to list

Readressing the rationale of irradiation in stage I seminoma guidelines : a critical essay

Charlien Berghen, Maarten Albersen, Pierre Blanchard, Alberto Bossi, Alberto Briganti, Cesare Cozzarini, Karel Decaestecker (UGent) , Valerie Fonteyne (UGent) , Karin Haustermans, Steven Joniau, et al.

(2019) BJU INTERNATIONAL. 124(1). p.35-39

Add to list

Assessing the role and optimal duration of hormonal treatment in association with salvage radiation therapy after radical prostatectomy : results from a multi-institutional study

Nicola Fossati, Daniele Robesti, R. Jeffrey Karnes, Matteo Soligo, Stephen A. Boorjian, Alberto Bossi, Gabriele Coraggio, Nadia Di Muzio, Cesare Cozzarini, Barbara Noris Chiorda, et al.

(2019) EUROPEAN UROLOGY. 76(4). p.443-449

Add to list

Metastasis-directed therapy in treating nodal oligorecurrent prostate cancer : a multi-institutional analysis comparing the outcome and toxicity of stereotactic body radiotherapy and elective nodal radiotherapy

Elise De Bleser (UGent) , Barbara Alicja Jereczek-Fossa, David Pasquier, Thomas Zilli, Nicholas Van As, Andrei Fodor, Piet Dirix, Alfonso Gomez-Iturriaga, Fabio Trippa, Shankar Siva, et al.

(2019) EUROPEAN UROLOGY. 76(6). p.732-739

Add to list

Journal Article
A1
open access

Reply to J.-E. Bibault et al, B. Tombal, and C. Cattrini et al

Piet Ost (UGent) , Dries Reynders (UGent) , Karel Decaestecker (UGent) , Valerie Fonteyne (UGent) , Nicolaas Lumen (UGent) , Bieke Lambert (UGent) , Louke Delrue (UGent) and Gert De Meerleer (UGent)

(2018) JOURNAL OF CLINICAL ONCOLOGY. 36(22). p.2351-2352

Add to list

Evaluating the current place of radiotherapy as treatment option for patients with muscle invasive bladder cancer in Belgium

Valerie Fonteyne (UGent) , Elke Rammant (UGent) , Piet Ost (UGent) , Yolande Lievens (UGent) , Bart De Troyer, Sylvie Rottey (UGent) , Gert De Meerleer, Daan De Maeseneer (UGent) , Dirk De Ridder and Karel Decaestecker (UGent)

(2018) CLINICAL GENITOURINARY CANCER. 16(6). p.e1159-e1169

Academic Bibliography

A trial-based cost-utility analysis of metastasis-directed therapy for oligorecurrent prostate cancer

A deep learning approach validates genetic risk factors for late toxicity after prostate cancer radiotherapy in a REQUITE Multi-National Cohort

Patient- versus physician-reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within a randomized controlled trial

What is oligometastatic prostate cancer?

Metastasectomy for visceral and skeletal oligorecurrent prostate cancer

Readressing the rationale of irradiation in stage I seminoma guidelines : a critical essay

Assessing the role and optimal duration of hormonal treatment in association with salvage radiation therapy after radical prostatectomy : results from a multi-institutional study

Metastasis-directed therapy in treating nodal oligorecurrent prostate cancer : a multi-institutional analysis comparing the outcome and toxicity of stereotactic body radiotherapy and elective nodal radiotherapy

Reply to J.-E. Bibault et al, B. Tombal, and C. Cattrini et al

Evaluating the current place of radiotherapy as treatment option for patients with muscle invasive bladder cancer in Belgium

Contents

Support

Contact